Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a lower dose of inactivated polio vaccine
(IPV) injected into the skin (intradermal administration) can work equally well or better
than the standard dose injected into the muscle (intramuscular administration). There are
more immune cells in the skin than in the muscle, and other vaccines have been shown to
require a lower dose when administered intradermally. The study is being done in participants
infected with HIV because HIV-infected people are known to respond less well to vaccines than
other groups, so it is particularly important to know if IPV might work better in
HIV-infected people if administered intradermally.
If it is possible to lower the dose of IPV by intradermal administration, this would make
inactivated polio vaccine more affordable in the developing countries where it is most needed